Relaxin treatment reverses insulin resistance in mice fed a high-fat diet

Diabetes

Volumn 62, Issue 9, 2013, Pages 3251-3260

  Bonner, Jeffrey S ^a   Lantier, Louise ^a   Hocking, Kyle M ^a   Kang, Li ^a   Owolabi, Mark ^a   James, Freyja D ^a   Bracy, Deanna P ^a   Brophy, Colleen M ^a   Wasserman, David H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTHERA; GLUCOSE; INSULIN; RELAXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; DRUG EFFECT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; GLUCOSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; RELAXIN;

EID: 84887338159     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0033     Document Type: Article

References (62)

1. Kang L, Ayala JE, Lee-Young RS, et al. Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin alpha2beta1 in mice. Diabetes 2011;60:416-426
2. Berria R, Wang L, Richardson DK, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab 2006;290:E560-E565
3. Gavin TP, Stallings HW 3rd, Zwetsloot KA, et al. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. J Appl Physiol 2005;98:315-321
4. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-379
5. Baron AD, Clark MG. Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 1997;17:487-499
6. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994;267:E187-E202
7. Baron AD, Tarshoby M, Hook G, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes 2000;49:768-774
8. Baron AD, Steinberg H, Brechtel G, Johnson A. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol 1994;266:E248-E253
9. Vincent MA, Clerk LH, Lindner JR, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004;53:1418-1423
10. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-1852
11. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991;73:637-643
12. Fueger PT, Shearer J, Bracy DP, et al. Control of muscle glucose uptake: test of the rate-limiting step paradigm in conscious, unrestrained mice. J Physiol 2005;562:925-935
13. Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab 2009;296:E11-E21
14. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1982-1988
15. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in en-dothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294-307
16. Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol 2011;31:15-32
17. McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 2011;152:2786-2796
18. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 2008;149:3286-3293
19. Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005;46:412-418
20. Conrad KP. Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension 2010;56:2-9
21. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 2011; 57:1151-1160
22. Segal MS, Sautina L, Li S, et al. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 2012; 119:629-636
23. Unemori EN, Lewis M, Constant J, et al. Relaxin induces vascular endo-thelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 2000;8:361-370
24. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996;98: 2739-2745
25. Yoshida T, Kumagai H, Suzuki A, et al. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transplant 2012;27.
26. Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 2010;151:4938-4948
27. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005;68:96-109
28. Jeyabalan A, Novak J, Doty KD, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 2007; 148:189-197
29. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55:390-397
30. Berglund ED, Li CY, Poffenberger G, et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 2008;57:1790-1799
31. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007;56:1025-1033
32. Wasserman DH, Ayala JE, McGuinness OP. Lost in translation. Diabetes 2009;58:1947-1950
33. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15-24
34. Lee-Young RS, Griffee SR, Lynes SE, et al. Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem 2009;284:23925-23934
35. Jørgensen SB, Viollet B, Andreelli F, et al. Knockout of the a2 but not a1 59-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004;279:1070-1079
36. Eagle S, Brophy CM, Komalavilas P, et al. Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function. Am Surg 2011;77:922-928
37. Hocking KM, Brophy C, Rizvi SZ, et al. Detrimental effects of mechanical stretch on smooth muscle function in saphenous veins. J Vasc Surg 2011; 53:454-460
38. Muhs BE, Gagne P, Plitas G, Shaw JP, Shamamian P. Experimental hin-dlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and-9 activity: a potential mechanism for ischemia induced MMP activation. J Surg Res 2004;117:249-254
39. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005;46:745-750
40. Guo Q, Mori T, Jiang Y, et al. Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats. Hyperten Res 2013;35:48-54
41. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N (v)-nitro-L-arginine methyl ester hypertensive rats. Hypertension 2011;58: 197-204
42. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, Dansky HM. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 2005;96:1178-1184
43. Ma L, Ma S, He H, et al. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 2010;33:446-453
44. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987;80:415-424
45. Mårin P, Andersson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994;17:382-386
46. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97: 2601-2610
47. Bonner JS, Lantier L, Hasenour CM, James FD, Bracy DP, Wasserman DH. Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance. Diabetes 2013; 62:572-580
48. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003;285:E123-E129
49. Halls ML, van der Westhuizen ET, Bathgate RA, Summers RJ. Relaxin family peptide receptors-former orphans reunite with their parent ligands to activate multiple signaling pathways. Br J Pharmacol 2007;150:677-691
50. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev 2013;93:405-480
51. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyper-insulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744
52. Zaman AK, Fujii S, Goto D, et al. Salutary effects of attenuation of an-giotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004;37:525-535
53. Shimizu M, Umeda K, Sugihara N, et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46:32-36
54. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011;300:G697-G702
55. MacDonald GA, Bridle KR, Ward PJ, et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16:599-606
56. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134-2140
57. Hedblad B, Nilsson P, Engström G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002;19:470-475
58. De Boer MP, Meijer RI, Wijnstok NJ, et al. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Microcirculation 2012;19:5-18
59. Utsunomiya KA. Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance. Vasc Health Risk Manag 2012;8:429-436
60. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 2012;19:F1-F8
61. Feng S, Agoulnik IU, Bogatcheva NV, et al. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007;13:1695-1702
62. Feng S, Agoulnik AI. Expression of LDL-A module of relaxin receptor in prostate cancer cells inhibits tumorigenesis. Int J Oncol 2011;39:1559-1565